CLD Updates: Velpatasvir/Sofosbuvir, Serum markers for hepatocellular carcinoma and Type 2 diabetes

View recently published articles in the latest issue of Clinical Liver Disease (CLD).

Volume 8 Issue 2  Issue Publication: August 2016

CLD is the official digital educational resource from the American Association for the Study of Liver Diseases.

Category Reviews New Treatments for HCV

Velpatasvir and sofosbuvir: How will we use a new drug when the old agents work well?
The rapid development of highly efficacious and well-tolerated regimens for treatment of chronic hepatitis C virus (HCV) infection has been a remarkable advance. Direct-acting antiviral combinations are available for each of the six HCV genotypes (GTs). Because sustained virological response (SVR) rates are greater than 95% for most patient populations, it may be questioned why new regimens are under development.​
Watch a video presentation of this article

Biomarkers in Liver Disease
Serum markers for hepatocellular carcinoma
Authors Paul ClarkFirst Published: 29 August 2016
Watch a video presentation of this article

Biomarkers of immunosuppression

Authors Tiong Yeng Lim, Michael HeneghanFirst Published: 29 August 2016
Watch a video presentation of this article
Watch the interview with the author

Hepatocellular Carcinoma and Nonalcoholic Steatohepatitis
Statins and metformin for chemoprevention of hepatocellular carcinoma

Authors Jonggi Choi, Lewis R. RobertsFirst Published: 29 August 2016
Watch a video presentation of this article Free Article Category

Type 2 diabetes–associated hepatocellular carcinoma: A molecular profile

Authors Manon Allaire, Jean Charles NaultFirst Published: 29 August 2016
Watch a video presentation of this article
Watch the interview with the author

Begin here...